BV100 Philippines trial plans list two hospitals. Witfire checks RIV-TARGET, revised readout dates, the antibiotic regimen and pending local recruitment.

Nerandomilast Philippines trial plans name three hospitals. Inside the Phase 3 systemic sclerosis study, its evidence, endpoints and pending local recruitment.

Alevia-B is receiving fresh coverage in the Philippines through PascualLab’s 80th-anniversary portfolio campaign. Each tablet combines paracetamol with vitamins B1, B6 and B12. The Philippine FDA ...

The FDA CPR renewal rule is narrower than a general grace period. A medical-device certificate can remain valid after its printed expiry while FDA review is pending, but only when the renewal was ...

RENGEVITY-201 trial dosing has begun, Veloxis says, with the first participant now treated. The Phase 2 study plans to randomise up to 120 kidney-transplant recipients across two pegrizeprument doses ...

A bright clinical concept image showing the stabilizer ceiling in amyloidosis, where modern background therapy reduces the detectable benefit of add-on drugs. HELIOS-B cleared its endpoint.

Bright scientific image illustrating eplontersen TTR silencing in transthyretin amyloid cardiomyopathy, cardiac amyloid burden and the challenge of adding a silencer to stabilizer therapy. HELIOS-B ...

RP1 showed a roughly one-in-three response rate, durable activity, and a favorable safety profile in anti-PD-1-failed advanced melanoma. The FDA rejected it anyway — not because the drug had obviously ...

Merck priced the first oral PCSK9 inhibitor at $10.50 a tablet. Amgen has been selling Repatha, in cash, for roughly eight dollars a day since October. That is the whole trade in two lines, and most ...

Moderna argued that the design had been discussed with CBER before the trial, that the comparator was FDA-approved, and that a separate Phase 3 study—P303 Part C—had already compared mRNA-1010 with a ...

Put this method on a file you are actually deciding. Witfire Elite provides pharmaceutical due diligence services built on the method used in every brief published here: every figure traced to a ...